Upadhyay Amitabh Kumar, Nag Deb Sanjay, Jena Sanghamitra, Sinha Neetesh, Lodh Dona
Medical Oncology, Tata Main Hospital, Jamshedpur, IND.
Anesthesiology, Tata Main Hospital, Jamshedpur, IND.
Cureus. 2024 Dec 5;16(12):e75142. doi: 10.7759/cureus.75142. eCollection 2024 Dec.
Biomarkers have the potential to play a crucial role in managing gallbladder cancer post-surgery. They can identify patients more likely to experience a recurrence, allowing oncologists to tailor a more intensive surveillance plan and consider additional therapies. Some biomarkers can even predict how well a patient will respond to specific chemotherapy or targeted treatments. By monitoring these biomarkers, clinicians can track how effective the ongoing treatment is and detect any signs of early recurrence. Various biomarkers, like tumor markers, genetic markers, and genomic and epigenetic markers, are being investigated. The goal is to find the most reliable and accurate biomarkers to enhance patient care and outcomes. Integrating biomarker data into treatment plans can help personalize therapy and make better informed decisions. By identifying which patients are likely to benefit from specific treatments, biomarkers have the potential to improve long-term survival rates significantly. This scoping review discusses newer biomarkers in gallbladder carcinoma; some of them are in clinical use, while most of them are used in research settings. This provides a broad insight to practicing clinicians about the present biomarkers and the futuristic biomarkers.
生物标志物在胆囊癌术后管理中可能发挥关键作用。它们能够识别更有可能复发的患者，使肿瘤学家能够制定更密集的监测计划并考虑额外的治疗方法。一些生物标志物甚至可以预测患者对特定化疗或靶向治疗的反应情况。通过监测这些生物标志物，临床医生可以追踪正在进行的治疗效果，并检测任何早期复发的迹象。目前正在研究各种生物标志物，如肿瘤标志物、基因标志物以及基因组和表观遗传标志物。目标是找到最可靠、最准确的生物标志物，以改善患者护理和治疗结果。将生物标志物数据整合到治疗计划中有助于实现个性化治疗并做出更明智的决策。通过确定哪些患者可能从特定治疗中获益，生物标志物有潜力显著提高长期生存率。本综述讨论了胆囊癌中更新的生物标志物；其中一些已在临床应用，而大多数仍用于研究环境。这为临床医生提供了关于当前生物标志物和未来生物标志物的广泛见解。
